StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) Sees Quick Sell-Off Following FDA Briefing Docs
April 21, 2016 8:08 AM
Sarepta Therapeutics (NASDAQ: SRPT) ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Momentum Movers
Short Sales
Trader Talk
Next Articles
RBC Sees Odds on Sarepta (SRPT) 9:1 Against
April 22, 2016 9:27 AM
Wedbush Downgrades Sarepta Therapeutic (SRPT) to Neutral (Yesterday)
April 22, 2016 7:24 AM
Buy Sarepta Therapeutic (SRPT) on Sell-Off - Needham & Company
April 22, 2016 6:40 AM
Sarepta (SRPT) PT Lowered to $23 at Baird as FDA Digs in for a Fight on Eteplirsen
April 21, 2016 4:53 PM
Oppenheimer Maintains Bullish View on Sarepta (SRPT) Despite Sell-Off on FDA Briefing Documents
April 21, 2016 1:20 PM
William Blair Downgrades Sarepta Therapeutic (SRPT) to Market Perform
April 21, 2016 12:54 PM
FDA Not Changing Etep Stance (SRPT) (BMRN) - Leerink
April 21, 2016 11:22 AM
CRL 'Most Logical Outcome' for Sarepta's (SRPT) Eteplirsen - Janney Montgomery Scott
April 21, 2016 9:29 AM
Sarepta Therapeutics (SRPT) on watch as FDA briefing documents hit
April 21, 2016 8:00 AM
Janney Capital Starts Sarepta Therapeutic (SRPT) at Neutral
April 20, 2016 8:03 AM
4-Year Loss of Ambulation Data Demonstrates Sarepta's (SRPT) Eteplirsen Benefit - Oppenheimer
April 20, 2016 6:59 AM
